Helio Genomics partnered with Syneos Health to broaden commercialization of its blood-based HelioLiver test for early detection of hepatocellular carcinoma. Financial terms were not disclosed, but the collaboration is framed around scaling healthcare provider adoption across the US. HelioLiver uses an AI-based approach combining cell-free DNA methylation patterns, protein biomarkers, and patient demographics to identify HCC risk. The company has already expanded distribution through previous commercialization arrangements, including co-branding with Fulgent Genetics and availability through Quest Diagnostics-affiliated providers. The Syneos partnership is positioned as an acceleration of market penetration, with Syneos expected to leverage its commercial execution capabilities to increase utilization and referral workflows.